Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9J6XV
|
|||
| Drug Name |
Vobarilizumab
|
|||
| Synonyms |
ALX-0061
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [2] | ||
| Company |
Ablynx
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02518620) An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02437890) A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Ablynx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.